Skip to main content
MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED logo

MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · MVP ISIN · AU000000MVP2 LEI · 9845007EAECAOD1U4493 ASX Manufacturing
Open in API
Filings indexed 908 across all filing types
Latest filing 2018-09-09 Investor Presentation
Country AU Australia
Listing ASX MVP

About MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED

https://medicaldev.com

Medical Developments International Limited specializes in the development and distribution of emergency pain relief and respiratory products. The company's flagship product is Penthrox, a handheld, self-administered inhaler providing rapid-onset, non-opioid analgesia using methoxyflurane. Penthrox is utilized globally by emergency medical services, hospitals, and for procedural pain in various clinical settings. Additionally, the company manufactures a range of respiratory medical devices, including anti-static spacers and asthma management tools designed to optimize medication delivery. The organization focuses on providing portable, effective solutions for acute pain management and respiratory care, catering to healthcare professionals and patients in emergency, surgical, and primary care environments.

Recent filings

Filing Released Lang Actions
CEO Roadshow Presentation 42 pages 1.7MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation from Medical Developments International dated September 2018. It contains forward-looking statements, product updates, regulatory approval statuses, clinical trial pipelines, and market outlooks. The content is structured as a presentation with slides, images (omitted), and detailed narrative on product development, regulatory interactions, and sales progress. There is no indication that this is an official annual report, audit report, earnings release, or regulatory filing. Instead, it fits the profile of an investor presentation focusing on financials, strategy, and market position. The length (15,000 characters) and detailed content support this classification rather than a brief announcement or a formal report. Therefore, the document is best classified as an Investor Presentation (IP).
2018-09-09 English
Update - Dividend/Distribution - MVP 4 pages 35.0KB
Notice of Dividend Amount Classification · 100% confidence The document is titled 'Notification of dividend / distribution' and contains detailed information about a dividend payment, including dividend amount, record date, payment date, franking details, and dividend reinvestment plan (DRP) specifics. It is an announcement regarding the dividend amount and related payment details rather than a full financial report or earnings release. The content matches the definition of a Notice of Dividend Amount filing, which announces dividend amounts, payment dates, and shareholder details.
2018-09-03 English
Penthrox Paediatric Trial Safety Update 2 pages 134.7KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 30 August 2018 providing a safety update on a paediatric clinical trial for the drug Penthrox. It discusses the Data and Safety Monitoring Board's review and approval to continue the trial without modifications. The content is focused on clinical trial progress and safety data rather than financial results, management changes, or regulatory filings. The document length is 3812 characters, which is relatively short and does not contain detailed financial statements or comprehensive report data. It is an update announcement related to clinical trial safety, not a full report or regulatory filing. Therefore, it fits best under the category of Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2018-08-29 English
Penthrox USA Update 3 pages 148.5KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 29 August 2018 from Medical Developments International Limited regarding correspondence from the US FDA about their Investigative New Drug (IND) application for Penthrox. The content focuses on regulatory feedback and additional information requested by the FDA related to clinical trial design, manufacturing, labeling, and safety testing. There are no financial statements, earnings data, or detailed financial analysis. The document is a regulatory update on the status of the IND application and the company's response plans. It is not a full report, earnings release, or management discussion. The document is a regulatory announcement about ongoing FDA interactions and development progress, fitting best under Regulatory Filings (RNS). The document length is about 5999 characters, which is relatively short and consistent with an announcement rather than a full report.
2018-08-28 English
Share Purchase Plan (SPP) Offer 15 pages 442.9KB
Capital/Financing Update Classification · 95% confidence The document is a detailed communication from Medical Developments International Limited to its shareholders regarding a Share Purchase Plan (SPP). It includes terms and conditions, offer details, pricing, timetable, use of funds, and participation instructions. The content focuses on a capital raising activity through issuing new shares to existing shareholders at a discount, with details on subscription limits, scaling back, and regulatory compliance references (ASIC Class Order and ASX Listing Rules). There is no indication that this is a full financial report, earnings release, or management discussion. It is not a proxy statement, voting results, or board change announcement. The document is not a brief factsheet or presentation but a formal announcement of a financing activity. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and detail support this classification with high confidence.
2018-08-21 English
Preliminary Final Report and Full Year Accounts 78 pages 3.0MB
Annual Report Classification · 95% confidence The document is titled 'Medical Developments International Limited. Appendix 4E Results for Announcement to the Market' and contains detailed financial results for the year ended 30 June 2018, including revenue, profit, earnings per share, dividends, net tangible assets, and a Chairman and CEO report. It also references the audited Financial Report for the year ended 30 June 2018 and associated results announcement. The content includes comprehensive financial data, business performance, clinical developments, and market updates for the fiscal year, which aligns with the characteristics of an Annual Report. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement or certification. Therefore, the document fits the definition of an Annual Report (10-K). FY 2018
2018-08-16 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.